Intrathecal rituximab for EBV-associated post-transplant lymphoproliferative disorder with central nervous system involvement unresponsive to intravenous rituximab-based treatments: a prospective study.

• Authors: M Wu, J Sun, Y Zhang, F Huang, H Zhou, Z Fan, L Xuan, G Yu, X Guo, M Dai, R Feng, Q Liu
• Journal: Bone marrow transplantation (Bone Marrow Transplant) Vol. 51 Issue 3 Pg. 456-8 (Mar 2016) ISSN: 1476-5365 [Electronic] England
• PMID: 26595071 (Publication Type: Clinical Trial, Letter, Research Support, Non-U.S. Gov't)

Chemical References

• Rituximab

Topics

• Administration, Intravenous
• Adolescent
• Adult
• Allografts
• Central Nervous System Diseases (drug therapy, etiology)
• Epstein-Barr Virus Infections (drug therapy, etiology)
• Hematopoietic Stem Cell Transplantation
• Herpesvirus 4, Human
• Humans
• Injections, Spinal
• Lymphoproliferative Disorders (therapy)
• Male
• Prospective Studies
• Rituximab (administration & dosage)